Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

One Centre, Single Ascending Dose and Double Blind Multiple Ascending Dose, Safety and Pharmacokinetics Phase I Study of CPL409116 Compound in Healthy Volunteers

Next Previous
X
Search
Trial Profile

One Centre, Single Ascending Dose and Double Blind Multiple Ascending Dose, Safety and Pharmacokinetics Phase I Study of CPL409116 Compound in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CPL 409116 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Celon Pharma

    • Most Recent Events

    • 24 Mar 2022 Status changed from recruiting to completed.
    • 10 Feb 2021 According to a Celon Pharma media release, it has successfully completed Phase 1A of this trial .Celon plans to initiate a multiple ascending dose Phase 1b study with safety, pharmacokinetic and pharmacodynamic evaluations in the next coming weeks and expects readouts from this study to be available at the end of 2Q 2021
    • 10 Feb 2021 Results published in the Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top